Abstract
Most COVID-19 patients experience a mild disease; a minority suffers from critical disease.
We report about a biomarker validation study regarding 296 patients with confirmed SARS-CoV-2 infections from four tertiary care referral centers in Germany and France.
Patients with critical disease had significantly less anti-HCoV OC43 nucleocapsid protein antibodies compared to other COVID-19 patients (p=0.007). In multivariate analysis, OC43 negative inpatients had an increased risk of critical disease, higher than the risk by increased age or BMI, and lower than the risk by male sex. A risk stratification based on sex and OC43 serostatus was derived from this analysis.
Our results indicate that prior infections with seasonal human coronaviruses can protect against a severe course of COVID-19. Anti-OC43 antibodies should be measured for COVID-19 inpatients and considered as part of the risk assessment. We expect individuals tested negative for anti-OC43 antibodies to particularly benefit from vaccination, especially with other risk factors prevailing.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
DRKS00023322
Funding Statement
Supported by grants from BMBF (HiGHmed 01ZZ1802V, Use Case Infection Control; 01KI20152 RECOVER trial), Bavarian State Ministry for Sciences and Art (TP-10 and TP-11 to AEK), and National research network for University Medicine (NUM to AEK and MD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The following ethics committees gave approval to this study: Muenster: AZ 2020-210-f-S (Ethik-Kommission der Aerztekammer Westfalen-Lippe und der Westfaelischen Wilhelms-Universitaet Muenster) Heidelberg: S-148/2020 (Ethikkommission der Medizinischen Fakultaet Heidelberg) Paris: AAA-2020-08023 (Comite d'ethique de la Recherche de l'universite Paris Descartes) Erlangen: 174_20B (Ethikkommission der Friedrich-Alexander-Universitaet Erlangen-Nuernberg) Regensburg: 20-1785-101 (Ethikkommission bei der Universitaet Regensburg)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos